Voyager Therapeutics (FRA:VT6) Beginning Cash Position: €58.85 Mil (As of Mar. 2026)


FRA:VT6 Voyager Therapeutics Inc FRA:VT6
52 GF Score
Price €3.06
GF Value €1.47
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics Beginning Cash Position?

Voyager Therapeutics FRA:VT6 -2.05% 52 Beginning Cash Position is €58.85 Mil as of Mar. 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 52/100 and a GF Value™ of €1.47 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Voyager Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was €58.85 Mil.

Voyager Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 (€39.89 Mil) to Dec. 2025 (€43.33 Mil) and increased from Dec. 2025 (€43.33 Mil) to Mar. 2026 (€58.85 Mil).

Voyager Therapeutics's annual Beginning Cash Position declined from Dec. 2023 (€92.14 Mil) to Dec. 2024 (€67.23 Mil) and declined from Dec. 2024 (€67.23 Mil) to Dec. 2025 (€63.40 Mil).

Voyager Therapeutics Beginning Cash Position Related Terms

Voyager Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Beginning Cash Position Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.00 112.54 92.14 67.23 63.40

Voyager Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.67 67.30 39.89 43.33 58.85
FRA:VT6
52GF Score
Voyager Therapeutics Inc FRA:VT6
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €58.85 Mil mean?
Voyager Therapeutics (FRA:VT6) has a Beginning Cash Position of €58.85 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Beginning Cash Position too high?
Voyager Therapeutics' current Beginning Cash Position is €58.85 Mil. Overall, Voyager Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Beginning Cash Position compare to KROS and CDXS?
Voyager Therapeutics' Beginning Cash Position of €58.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Beginning Cash Position is €58.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.47, compared to a current price of €3.06 — trading 107.9% above its estimated fair value. The current Beginning Cash Position is €58.85 Mil. Voyager Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Beginning Cash Position is €58.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.06 is trading 107.9% above its estimated GF Value™ of €1.47. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Beginning Cash Position: €58.85 Mil
  • GF Value™: €1.47 vs. price of €3.06 (107.9% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score

Get the complete analysis for FRA:VT6

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€1.47
GF Value